Σημειώσεις επεισοδίου
Is secukinumab effective for active, moderate-to-severe Graves orbitopathy?
In a randomised trial, secukinumab did not improve clinical response compared with placebo at 16 weeks.
Randomised trial · Journal of Clinical Endocrinology & Metabolism 2026
Reference: Wolf J, et al. Secukinumab in moderate-to-severe Graves orbitopathy: a randomised, double-blind, placebo-controlled multicentre study. J Clin Endocrinol Metab. 2026;111(5):1248-1257. doi:10.1210/clinem/dgaf655. PMID: 41362233. https://pubmed.ncbi.nlm.nih.gov/41362233/
AI-narrated episode. For healthcare professionals; educational…
Ιστότοπος: listen.hubhopper.com

